hline1.jpg (2302 bytes) PRESS ROOM hline1.jpg (2302 bytes)

Aurobindo receives second ANDA approval from US FDA for PEPFAR
Aurobindo receives the first ARV approval from US FDA
USFDA approval received for Unit VIII Facility
Aurobindo receives NABL approval for its Clinical Laboratory
Aurobindo records improved performance quarter on quarter
Successful USFDA Inspection of one more Unit
Obtains 3rd product approval from USFDA
Aurobindo in Forbes list
Best under a Billion - Asia's Rising Companies
Aurobindo receives US FDA approval for Citalopram
A robust generic product portfolio to unveil.
Aurobindo obtains two product approvals from US FDA
Records Rs.272 crore turnover in Q2
First product approval from US FDA received Foray into Regulated Market crosses first major milestone
Company scientists conferred awards
Speech by the Chairman, Mr. P. V. Ramaprasad Reddy at the Annual General Meeting on 31st July 2004
Aurobindo posts Rs.2873 Millions sales and Rs.180 Million profit
Aurobindo net profit at Rs. 127 crs surges by 23%
UK MHRA (UK MCA) approval received for Unit 3
Subscription to preferential issue of equity shares
Aurobindo Q3 PAT grows by 68% Exports soar to 51% of sales
Aurobindo gets its first CoS approval from EDQM & files DMF for Citalopram
Aurobindo's Q2 Net Profit jumps to Rs.321.5 million, spurt by 57%
Preferential Issue of Equity Shares
Aurobindo net profit spurts by 52.75% in Q1
Aurobindo crosses the landmark Net Profit of Rs.100 crores
Aurobindo's demonstration of R&D leadership in cephalosporins
Aurobindo Pharma launches cefepime
Second quarter profit jumps  41.13%
Aurobindo implementing ERP package
Aurobindo posts Net Profit of  Rs. 68.51 crores
Noted Cardiologist Dr. I. Satyamurthy joins Aurobindo Board
Aurobindo Pharma wins award for the best bulk drug company
Shares allotted to Templeton
Brazilian GMP certification received for the speciality generic formulations unit
Aurobindo Pharma acquires equity in Ranit Pharma
Mr. Lanka Srinivas inducted as Additional Director on Board of Aurobindo Pharma
Aurobindo Pharma launches Aztreonam for the first time in India  
Aurobindo Pharma & Citadel promote a joint venture
Aurobindo Pharma welcomes excise duty exemption on anti-HIV drugs in budget
Aurobindo launches Cefactam (Cefoperazone plus Salbactam)
4th generation Cephalosporin – Cefpirome launched
Impressive Q3 performance 
Aurobindo shareholders approve Rs.125 crore Private Placement
Templeton to pick up equity
Aurobindo Pharma Board approves Rs. 125 crore private placement
Aurobindo Pharma launches two more antiretroviral products for HIV treatment
Restructuring on track
Aurobindo introduces two more drugs for treatment of Aids
Imunus Aurobindo launches two new anti-aids drugs
Aurobindo Pharma slashes prices of anti-aids drugs
Restructuring of Facilities
Income crosses Rs. 1000 crore land mark

www.aurobindo.com

Hyderabad, 30th June, 2002

AUROBINDO'S Q1 NET PROFIT GROWS BY 34%

Aurobindo Pharma Ltd. has reported excellent results for the quarter ended 30th June 2002.  The Total Income for the quarter stood at Rs.25042 lacs (Rs. 18996 lacs), an increase of 32% over the corresponding period in the previous year.

The Profit before Depreciation, Interest and Tax for the quarter stood at Rs.3692 lacs (Rs.2693 lacs).After providing Rs.1280 lacs (Rs.1101 lacs) for Interest, Rs.393 lacs (Rs.365 lacs) for Depreciation the profit before tax stood at 2019 lacs (1227 lacs) registering a sharp increase of 65%. With a provision of Rs.510 lacs (Rs.100 lacs) towards tax, the Net Profit stood at Rs.1509 lacs (Rs.1127 lacs), registering a growth of 34% over the corresponding period in the previous year.

Export sales in the first quarter at Rs.11633 lacs registered a 40% growth over the corresponding period in the previous year. Domestic sales in the first quarter grew by 23% to Rs.13091 lacs.

Aurobindo has invested around Rs.150 cores in the recent quarters in key projects such as 100% China subsidiary, 100% Brazil subsidiary, 50% joint venture in USA and the regulatory dmf and back up investments in two manufacturing facilities at Hyderabad and R&D. These investments are progressing fast but have had an impact on interest cost of the Company. The Company expects the benefits from these projects to accrue beginning from the third quarter. Further the benefits of domestic restructuring shall be more visible on the completion of mega bulk API site at Vizag, which is expected to commence production in the third quarter of this year.

On completion of these projects in regulated and semi-regulated markets, the company can look forward to sustained and rapid growth in the long term. Obviously, economies of scale, entry into regulated markets and product and geographical expansion in semi-regulated markets are expected to result in a positive impact on both the top line and the bottom line of the company.The dream of Aurobindo Pharma to become an R&D led world class international pharmaceutical company is materializing speedily and healthily.

Top

________________________________________________________________